BSR Statement on EMEA Annoucement on COX II Inhibitors
BSR Statement on Johnson & Johnson Actions in Remicade Labelling
Document Actions
12 October 2004
The British Society for Rheumatology acknowledges Johnson & Johnson’s announcement of a change to US labelling of Remicade to inform patients with rheumatoid arthritis that taking the drug may have a higher risk of lymphoma. We are aware that European labelling has included this information for some time. In the UK we are in a good position to monitor the potential risk as data on the use of all Anti-TNFα drugs is collected on the British Society for Rheumatology Biologics Register. In terms of the current data available on the register we have not identified any obvious rise in lymphoma cases in patients with rheumatoid arthritis who are on these drugs.